When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
BTX - BioTime doses first patient with new formulation of OpRegen
Brooklyn ImmunoTherapeutics Inc.
The first patient has been dosed with BioTime's (BTX) new off-the-shelf Thaw-and-Inject formulation of OpRegen using the Orbit Subretinal Delivery System (Orbit SDS) in a Phase 1/2a clinical trial in patients with dry age-related macular degeneration.
More news on: BioTime, Inc., Healthcare stocks news,